These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 22974249

  • 1. Cardioselective beta-blocker treatment of hypertension in patients with asthma: when do benefits outweigh risks?
    Self TH, Wallace JL, Soberman JE.
    J Asthma; 2012 Nov; 49(9):947-51. PubMed ID: 22974249
    [Abstract] [Full Text] [Related]

  • 2. Beta-blocker underuse in secondary prevention of myocardial infarction.
    Everly MJ, Heaton PC, Cluxton RJ.
    Ann Pharmacother; 2004 Feb; 38(2):286-93. PubMed ID: 14742768
    [Abstract] [Full Text] [Related]

  • 3. Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma.
    Self T, Rogers ML, Mancell J, Soberman JE.
    Am J Med Sci; 2011 Jul; 342(1):56-61. PubMed ID: 21293248
    [Abstract] [Full Text] [Related]

  • 4. [Atenolol or metoprolol as beta-blocker in the treatment of hypertension].
    van den Born BJ, Brewster LM, Koopmans RP, van Montfrans GA.
    Ned Tijdschr Geneeskd; 2005 Aug 06; 149(32):1808-9. PubMed ID: 16121668
    [Abstract] [Full Text] [Related]

  • 5. Benefits of non-selective versus cardioselective beta-blockers in acute myocardial infarction in hypertensive patients.
    Hansen O, Johansson BW.
    J Hypertens Suppl; 1993 Jun 06; 11(4):S55-60. PubMed ID: 8104242
    [Abstract] [Full Text] [Related]

  • 6. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers.
    Brooks TW, Creekmore FM, Young DC, Asche CV, Oberg B, Samuelson WM.
    Pharmacotherapy; 2007 May 06; 27(5):684-90. PubMed ID: 17461703
    [Abstract] [Full Text] [Related]

  • 7. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar 06; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 8. The evolving role of β-adrenergic receptor blockers in managing hypertension.
    Poirier L, Lacourcière Y.
    Can J Cardiol; 2012 May 06; 28(3):334-40. PubMed ID: 22595449
    [Abstract] [Full Text] [Related]

  • 9. [Administration of cardioselective beta-adrenoblockers in patients with arterial hypertension and/or ischemic heart disease associated with bronchoobstructive syndrome].
    Ovcharenko SI, Litvinova IV, Mikolkin VI.
    Ter Arkh; 2007 May 06; 79(9):12-8. PubMed ID: 18038580
    [Abstract] [Full Text] [Related]

  • 10. Implication of different initial beta blockers on treatment persistence: atenolol vs new-generation beta blocker, a population-based study.
    Choi YJ, Ah YM, Kong J, Choi KH, Kim B, Han N, Yu YM, Oh JM, Shin WG, Lee HY, Lee JY.
    Cardiovasc Ther; 2016 Aug 06; 34(4):268-75. PubMed ID: 27214564
    [Abstract] [Full Text] [Related]

  • 11. Atenolol and metoprolol once daily in hypertension.
    Scott AK, Rigby JW, Webster J, Hawksworth GM, Petrie JC, Lovell HG.
    Br Med J (Clin Res Ed); 1982 May 22; 284(6328):1514-6. PubMed ID: 6805588
    [Abstract] [Full Text] [Related]

  • 12. The current state of beta blockers in hypertension therapy.
    Lardizabal JA, Deedwania PC.
    Indian Heart J; 2010 May 22; 62(2):111-7. PubMed ID: 21180299
    [Abstract] [Full Text] [Related]

  • 13. Beta-adrenergic antagonists in hypertension: a review of the evidence.
    Warmack TS, Estes MA, Heldenbrand S, Franks AM.
    Ann Pharmacother; 2009 Dec 22; 43(12):2031-43. PubMed ID: 19934392
    [Abstract] [Full Text] [Related]

  • 14. Portal-systemic encephalopathy and gastrointestinal bleeding after cardioselective beta-blocker (metoprolol) administration to patients with portal hypertension.
    Uribe M, Orozco H, Morán S, Guevara L, Poo JL, Vargas-Vorackova F.
    Arch Med Res; 1995 Dec 22; 26(3):221-6. PubMed ID: 8580671
    [Abstract] [Full Text] [Related]

  • 15. Dilated cardiomyopathy with hypertension: prevalence and response to high-dose β1-adrenoceptor antagonist therapy.
    Zheng X, Chen S, Wang J, Yang T, Chen Y.
    Clin Exp Pharmacol Physiol; 2009 Sep 22; 36(9):945-9. PubMed ID: 19473337
    [Abstract] [Full Text] [Related]

  • 16. Atenolol in hypertension: follow-up of patients crossed over to this agent from propranolol, pindolol or metoprolol.
    Frewin DB, Penhall RK, Leonello PP, Clapp RJ.
    N Z Med J; 1980 Nov 26; 92(672):389-90. PubMed ID: 6937768
    [Abstract] [Full Text] [Related]

  • 17. S-metoprolol: the 2008 clinical review.
    Dasbiswas A, Shinde S, Dasbiswas D.
    J Indian Med Assoc; 2008 Apr 26; 106(4):259-62. PubMed ID: 18828349
    [Abstract] [Full Text] [Related]

  • 18. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ, INVEST Investigators.
    Am Heart J; 2008 Aug 26; 156(2):241-7. PubMed ID: 18657652
    [Abstract] [Full Text] [Related]

  • 19. beta1- and beta2-adrenergic receptor gene variation, beta-blocker use and risk of myocardial infarction and stroke.
    Lemaitre RN, Heckbert SR, Sotoodehnia N, Bis JC, Smith NL, Marciante KD, Hindorff LA, Lange LA, Lumley TS, Rice KM, Wiggins KL, Psaty BM.
    Am J Hypertens; 2008 Mar 26; 21(3):290-6. PubMed ID: 18219297
    [Abstract] [Full Text] [Related]

  • 20. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
    Terra SG, Pauly DF, Lee CR, Patterson JH, Adams KF, Schofield RS, Belgado BS, Hamilton KK, Aranda JM, Hill JA, Yarandi HN, Walker JR, Phillips MS, Gelfand CA, Johnson JA.
    Clin Pharmacol Ther; 2005 Mar 26; 77(3):127-37. PubMed ID: 15735607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.